[A19-22] Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V

Last updated 03.06.2019

Project no.:
A19-22

Commission:
Commission awarded on 26.02.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication/Intervention:

Monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy

Result of dossier assessment:

Added benefit versus appropriate comparator therapy not proven due to lack of suitable study data

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.